Millennium Management’s Coherus Oncology CHRS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q3
Sell
-104,200
Closed -$1.46M 3935
2018
Q2
$1.46M Buy
+104,200
New +$1.49M ﹤0.01% 2615
2016
Q4
Sell
-100,000
Closed -$2.68M 3367
2016
Q3
$2.68M Buy
+100,000
New +$2.73M ﹤0.01% 1747
2015
Q4
Sell
-50,000
Closed -$1M 3445
2015
Q3
$1M Buy
+50,000
New +$1.52M ﹤0.01% 2282

Other funds holding CHRS

Millennium Management's CHRS Position: Q1 2026 in Review

Millennium Management reduced its Coherus Oncology (CHRS) stake by 53% in Q1 2026, selling an estimated $619K and leaving 311,986 shares worth $527K. The position accounts for ﹤0.01% of the portfolio, ranked #4742.

Millennium Management first reported a position in CHRS in Q1 2015 and has held it in 38 quarters since. The position peaked at $27M in Q3 2016. 157 funds tracked by Wall St. Rank hold CHRS as of Q1 2026.

  • Millennium Management held 311,986 shares of Coherus Oncology worth $527K as of Q1 2026.
  • Millennium Management sold 348,465 Coherus Oncology shares in Q1 2026, an estimated $619K.
  • Coherus Oncology made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #4742 holding.
  • Millennium Management first reported a position in Coherus Oncology in Q1 2015 and has held it in 38 quarters since.
  • Millennium Management's Coherus Oncology position peaked at $27M in Q3 2016.
  • 157 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.